bluebird bio Q2 EPS $(0.67) Beats $(0.72) Estimate, Sales $6.89M Miss $9.31M Estimate
Portfolio Pulse from Benzinga Newsdesk
bluebird bio (NASDAQ:BLUE) reported Q2 earnings per share of $(0.67), beating the analyst consensus estimate of $(0.71) by 5.63%. However, the company's quarterly sales of $6.89 million missed the analyst consensus estimate of $11.65 million by 40.86%. Despite the sales miss, this represents a 353.59% increase over sales from the same period last year.
August 08, 2023 | 11:02 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
bluebird bio's Q2 earnings beat estimates but sales missed. Despite the miss, sales are up significantly YoY.
While bluebird bio beat earnings estimates, the miss on sales could negatively impact investor sentiment. However, the significant YoY increase in sales may offset this to some extent, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100